Globulin generally refers to immunoglobulin. The onset of action of immunoglobulin treatment for Guillain-Barré syndrome is often 3 to 5 days, depending on the patient’s condition. Immunoglobulins are given intravenously and enter the body’s bloodstream, where they are rapidly distributed throughout the blood vessels. Patients with Guillain-Barré syndrome may experience significant relief of their symptoms after 3 to 5 days of intravenous immunoglobulin administration. If the patient’s condition is poor or severe, the time to onset of action may be prolonged. Adverse reactions such as headache, nausea, and panic may occur after the use of immunoglobulin. It is contraindicated in patients with hypersensitivity to immunoglobulin components and IgA deficiency. Patients with Guillain-Barré syndrome should visit the neurology department of the hospital in a timely manner, and under the guidance of the doctor, a comprehensive treatment program should be adopted to improve the condition. All drugs should be used under medical supervision.